Furthermore, using the TIDE website, it was determined that patients with downregulated expression levels of SOCS3 had a higher overall survival rate after ICB (PD-1 or PD-L1) treatment among kidney cancer, melanoma, and bladder cancer patients. Here, SOCS3 is linked to melanoma.